Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Insilico Medicine
Pharma
Merck and BioNTech's I-O bispecific buys—Fierce Pharma Asia
Merck and BioNTech bought Chinese biotechs to gain bispecifics. AZ and Daiichi refiled their TROP2 antibody-drug conjugate with the FDA. And more.
Angus Liu
Nov 15, 2024 8:20am
Innovation Honorees
Sep 9, 2024 5:01am
China deals, Enhertu, Samsung Bio—Fierce Pharma Asia
Jul 26, 2024 1:45am
BIO-WuXi, Takeda, FDA-Carvykti—Fierce Pharma Asia
Mar 15, 2024 10:15am
Capturing COVID: Biopharma through the lens during the pandemic
Nov 13, 2023 7:45am
Otsuka, Astellas, Exelixis and Insilico—Fierce Pharma Asia
Sep 15, 2023 9:00am